Selective small molecule induced degradation of the BET bromodomain protein BRD4

Michael Zengerle, Kwok-Ho Chan, Alessio Ciulli (Lead / Corresponding author)

Research output: Contribution to journalArticle

211 Citations (Scopus)
147 Downloads (Pure)

Abstract

The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1. However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting. We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins. Compound MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3. The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concentration not to induce stabilization of HIF-1α. Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4. Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with selective targeting of BRD4.

Original languageEnglish
Pages (from-to)1770-1777
Number of pages8
JournalACS Chemical Biology
Volume10
Issue number8
Early online date2 Jun 2015
DOIs
Publication statusPublished - 21 Aug 2015

Fingerprint

Proteolysis
Degradation
Molecules
Ubiquitin-Protein Ligases
Neoplasm Genes
Transcriptome
Epigenomics
Gene expression
Toxicity
Proteins
Stabilization
Genes
Ligands
Phenotype
Therapeutics
Neoplasms

Cite this

@article{d98f71d8c8a9430e850121055a6e7cb0,
title = "Selective small molecule induced degradation of the BET bromodomain protein BRD4",
abstract = "The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1. However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting. We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins. Compound MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3. The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concentration not to induce stabilization of HIF-1α. Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4. Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with selective targeting of BRD4.",
author = "Michael Zengerle and Kwok-Ho Chan and Alessio Ciulli",
year = "2015",
month = "8",
day = "21",
doi = "10.1021/acschembio.5b00216",
language = "English",
volume = "10",
pages = "1770--1777",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "8",

}

Selective small molecule induced degradation of the BET bromodomain protein BRD4. / Zengerle, Michael; Chan, Kwok-Ho; Ciulli, Alessio (Lead / Corresponding author).

In: ACS Chemical Biology, Vol. 10, No. 8, 21.08.2015, p. 1770-1777.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selective small molecule induced degradation of the BET bromodomain protein BRD4

AU - Zengerle, Michael

AU - Chan, Kwok-Ho

AU - Ciulli, Alessio

PY - 2015/8/21

Y1 - 2015/8/21

N2 - The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1. However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting. We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins. Compound MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3. The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concentration not to induce stabilization of HIF-1α. Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4. Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with selective targeting of BRD4.

AB - The Bromo- and Extra-Terminal (BET) proteins BRD2, BRD3, and BRD4 play important roles in transcriptional regulation, epigenetics, and cancer and are the targets of pan-BET selective bromodomain inhibitor JQ1. However, the lack of intra-BET selectivity limits the scope of current inhibitors as probes for target validation and could lead to unwanted side effects or toxicity in a therapeutic setting. We designed Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins. Compound MZ1 potently and rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3. The activity of MZ1 is dependent on binding to VHL but is achieved at a sufficiently low concentration not to induce stabilization of HIF-1α. Gene expression profiles of selected cancer-related genes responsive to JQ1 reveal distinct and more limited transcriptional responses induced by MZ1, consistent with selective suppression of BRD4. Our discovery opens up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with selective targeting of BRD4.

UR - http://www.scopus.com/inward/record.url?scp=84939788143&partnerID=8YFLogxK

U2 - 10.1021/acschembio.5b00216

DO - 10.1021/acschembio.5b00216

M3 - Article

C2 - 26035625

AN - SCOPUS:84939788143

VL - 10

SP - 1770

EP - 1777

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 8

ER -